Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 3, 1996, Pages 1040-1049

  Owens, Michael J ^a   Ballenger, Cynthia A ^a   Knight, David L ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; CARRIER PROTEIN; CHLORAMPHETAMINE; CITALOPRAM; CORTICOSTERONE; FENFLURAMINE; SEROTONIN; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG RECEPTOR BINDING; HYPERCORTISOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; THROMBOCYTE;

AMPHETAMINES; ANIMALS; BLOOD PLATELETS; BRAIN; BRAIN MAPPING; CARRIER PROTEINS; CITALOPRAM; CORTICOSTERONE; DEPRESSION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; P-CHLOROAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0030440890     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. APPEL, N. M., CONTRERA, J. F. AND DE SOUZA, E. B.: Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: Evidence from immunohistochemical studies. J. Pharmacol. Exp. Ther. 245: 928-943, 1989.
2. 3H]imipramine binding in rat blood platelets and brain. Eur. J. Pharmacol. 123: 415-419, 1986.
3. 2 binding sites in the frontal cortex of suicide victims and control subjects. Am. J. Psychiatry 146: 730-736, 1989a.
4. 3H-LSD in the blood platelets of depressed patients. Life Sci. 44: 725-734, 1989b.
5. ASTEE, R. H.: Studies of the mechanism of "hypersplenic" thrombocytopenia in rats. J. Lab. Clin. Med. 70: 736-751, 1967.
6. 2 receptor binding on blood platelets: A peripheral marker for depression? Life Sci. 41: 2485-2492, 1987.
7. 2 receptor binding on blood platelets of suicidal men. Psychopharmacology 100: 165-167, 1990a.
8. 2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology 102: 73-75, 1990b.
9. BRILEY, M. S., LANGER, S. Z., RAISMAN, R., SECHTER, D. AND ZARIFIAN, E.: Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science 209: 303-305, 1980.
10. CARROLL, B. J., CURTIS, G. C. AND MENDELS, J.: Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch. Gen. Psychiatry 38: 1039-1050, 1976.
11. 3H]-imipramine. J. Pharmacol. Exp. Ther. 242: 364-371, 1987.
12. 3H-paroxetine binding in depressed patients. Psychiatr. Res. 26: 11-17, 1988.
13. 3H]-paroxetine to platelets of depressed patients: Seasonal differences and effects of dignostic classification. J. Affective Disord. 32:27-35, 1994.
14. DA PRADA, M., CESURA, A. M., LAUNAY, J. M. AND RICHARDS, J. G.: Platelets as models for neurones? Experientia 44:115-126, 1988.
15. DE SOUZA, E. B. AND BATTAGLIA, G.: Effects of MDMA and MDA on brain serotonin neurons: Evidence from neurochemical and autoradiographic studies. In Pharmacology and Toxicology of Amphetamine and Related Drugs, ed. by K. Ashgar and E. B. De Souza, pp. 196-222, National Institute on Drug Abuse Research Monograph, Rockville, MD, 1989.
16. ELLIOT, J. M.: Peripheral markers in affective disorders. In Biological Aspects of Affective Disorders, ed. by R. Horton and C. Katona, pp. 95-144, Academic Press, London, 1991.
17. ELLIS, P. M. AND SALMOND, C.: Is platelet imipramine binding reduced in depression? A meta-analysis. Biol. Psychiatry 36: 292-299, 1994.
18. FREEMAN, A. M., STANKOVIC, S. M. I., BRADLEY, R. J., ZHANG, G. Z., LIBB, J. W. AND NEMEROFF, C. B.: Tritiated platelet imipramine binding and treatment response in depressed outpatients. Depression 1: 20-23, 1993.
19. 3H]-lysergic acid diethylamide binding to a 5-hydroxytryptamine receptor on human platelet membranes. Eur. J. Pharmacol. 97: 87-93, 1984.
20. 125I]R-DOI binding sites: Characterization by in vitro autoradiography. Neuropsychopharmacology 3: 25-32, 1990.
21. 2 sites in cortex and amygdala. Brain Res. 614: 37-44, 1993.
22. 3H-citalopram binding in response to saline injections or fenfluramine-induced lesions. Soc. Neurosci. Abstr. 19: 498, 1993.
23. 3H]paroxetine binding with the 5-HT transporter in brain and platelets: Relevance to studies in depression. J. Receptor Res. 7: 499-521, 1987.
24. 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci. 29: 211-218, 1981.
25. LANGER, S. Z. AND GALZIN, A-M.: Studies on the serotonin transporter in plate-lets. Experientia 44: 127-130, 1988.
26. 3H]paroxetine. Psychopharmacology 110: 235-239, 1993.
27. LEAKE, A., FAIRBAIRN, A. F., MCKEITH, I. G. AND FERRIER, I. N.: Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: Neurochemical and clinical correlates. Psychiatr. Res. 39: 155-165, 1991.
28. LESCH, K-P., WOLOZIN, B. L., MURPHY, D. L. AND REIDERER, P.: Primary structure of the human platelet serotonin uptake site: Identity with the brain serotonin transporter. J. Neurochem. 60: 2319-2322, 1993a.
29. LESCH, K-P., AULAKH, C. S., WOLOZIN, B. L., TOLLIVER, T. J., HILL, J. L. AND MURPHY, D. L.: Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol. Brain Res. 17: 31-35, 1993b.
30. LINKOWSKI, P., MENDLEWICZ, J., LECLERCQ, R., BRASSEUR, M., HUBAIN, P., GOLSTEIN, J., COPINSCHI, G. AND VAN CAUTER, E.: The 24 hour profile of adrenocorticotropin and cortisol in major depressive illness. J. Clin. Endocrinol. Metab. 61: 429-438, 1985.
31. LOPEZ, J. F., CHALMERS, D. T., VAZQUEZ, D. M., WATSON, S. J. AND AKIL, H.: Serotonin transporter mRNA in rat brain is regulated by classical antidepressants. Biol. Psychiatry 35: 287-290, 1994.
32. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
33. 2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiatry 43: 945-959, 1986.
34. MARCUSSON, J. O. AND ROSS, S. B.: Binding of some antidepressants to the 5-hydroxvtryptamine transporter in brain and platelets. Psychopharmacology 102: 145-155, 1990.
35. 2 receptors in rat brain. Neuropsychopharmacology 2: 81-87, 1989.
36. 3H-paroxetine binding to the serotonin transporter is insensitive to changes in central serotonergic innervation in the rat. Psychiatr. Res. 38: 97-104, 1991.
37. MUSSELMAN, D. L. AND NEMBROFF, C. B.: Adrenal function in major depression. The Endocrinologist 5: 91-96, 1995.
38. 3H]paroxetine binding in the frontal cortex and blood platelets of rats. Biochem. Pharmacol. 41: 79-84, 1991.
39. NEMEROFF, C. B., KNIGHT, D. L., KRISHNAN, K. R. R., SLOTKIN, T. A., BISSETTE, G., MELVILLE, M. L. AND BLAZER, D. G.: Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression. Arch. Gen. Psychiatry 45: 919-923, 1988.
40. NEMEROFF, C. B., KNIGHT, D. L., FRANKS J., CRAIGHEAD W. E. AND KRISHNAN, K. R. R.: Further studies on platelet serotonin transporter binding in depression. Am. J. Psychiatry 151: 1623-1625, 1994.
41. ODELL, T. T. JR., TAUSCHE, F. G. AND FURTH, J.: Platelet life span as measured by transfusion of isotopically labeled platelets into rats. Acta Haematol. 13: 45-52, 1955.
42. 2 receptor binding characteristics in the individual and the putative regulation by serotonin. J. Neural Transm. 93: 27-35, 1993.
43. 2 agonist, (±)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane (DOB) stimulates the hypothalamic-pituitary-adrenal (HPA) axis: II. Biochemical and physiological evidence for the development of tolerance after chronic administration. J. Pharmacol. Exp. Ther. 256: 795-800, 1991a.
44. OWENS, M. J., OVERSTREET, D. H., KNIGHT, D. L., REZVANI, A. H., RITCHIE, J. C., BISSETTE, G., JANOWSKY, D. S. AND NEMEROFF, C. B.: Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. Neuropsychopharmacology 4: 87-93, 1991b.
45. OWENS, M. J. AND NEMEROFF, C. B.: The role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 40: 288-295, 1994.
46. PANDEY, G. N., PANDEY, S. C. AND JANICAK, P. G.: Platelet serotonin-2 binding sites in depression and suicide. Biol. Psychiatry 28: 215-222, 1990.
47. 3H-imipramine to the platelet serotonin "transporter." Arch. Gen. Psychiatry 38: 1315-1317, 1981.
48. PERRY, E. K., MARSHALL, E. F., BLESSED, G., TOMLINSON, B. E. AND PERRY, R. H.: Decreased imipramine binding in the brains of patients with depressive illness. Br. J. Psychiatry 142: 188-192, 1983.
49. PIETRASZEK, M. H., TAKADA, Y., YAN, D., URANO, T., SERIZAWA, K. AND TAKADA, A.: Relationship between serotonergic measures in periphery and the brain of mouse. Life Sci. 51: 75-82, 1992.
50. PLETSCHER, A.: The 5-hydroxytryptamine system of blood platelets: physiology and pathophysiology. Int. J. Cardiol. 14: 177-188, 1987.
51. PLOTSKY, P. M., OWENS, M. J. AND NEMEROFF, C. B.: Neuropeptide alterations in affective disorders: focus on corticotropin releasing hormone, somatostatin and thyrotropin releasing hormone. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 971-982, Raven Press, New York, 1995.
52. QIAN Y., MELIKIAN, H. E., RYE, D. B., LEVEY, A. I. AND BLAKELY, R. D.: Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J. Neurosci. 15: 1261-1274, 1995.
53. RAMAMOORTHY, S., COOL, D. R., MAHESH, V. B., LEIBACH, F. H., MELIKIAN, H. E., BLAKELY, R. D. AND GANAPATHY, V.: Regulation of the human serotonin transporter. J. Biol. Chem. 268: 21626-21631, 1993.
54. SACHAR, E. J.: Neuroendocrine dysfuntion in depressive illness. Annu. Rev. Med. 27: 389-396, 1976.
55. SCANZELLO, C. R., HATZIDIMITRIOU, G., MARTELLO, A. L., KATZ, J. L. AND RICAURTE, G. A.: Serotonergic recovery after (±)3,4-(methylenedioxy)-methamphetamine injury: Observations in rats. J. Pharmacol. Exp. Ther. 264: 1484-1491, 1993.
56. 2 receptors. Neuropharmacology 31: 881-893, 1992.
57. SHELINE, Y. I., BARDGETT, M. E., JACKSON, J. L., NEWCOMER, J. W. AND CSERNANSKY, J. G.: Platelet serotonin markers and depressive symptomatology. Biol. Psychiatry 37: 442-447, 1995.
58. SPENCER R. L., MILLER, A. H., STEIN, M. AND MCEWEN, B. S.: Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary, and immune tissue. Brain Res. 549: 236-246, 1991.
59. 3H]imipramine binding sites are decreased in the frontal cortex of suicides. Science 216:1337-1339, 1982.
60. STANLEY, M. AND MANN, J. J.: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet I: 214-216, 1983.
61. 2 receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration. Biochem. Pharmacol. 39: 161-166, 1990.
62. WILL, P. C., CORTRIGHT, R. N. AND HOPFER, U.: Polyethylene glycols as solvents in implantable osmotic pumps. J. Pharm. Sci. 69: 747-749, 1980.
63. YAN, D., URANO, T., PIETRASZEK, M. H., SHIMOYAMA, I., UEMURA, K., KOJIMA, Y., SAKAKIBARA, K., SERIZAWA, K., YAKADA, Y. AND TAKADA, A.: Correlation between serotonergic measures in cerebrospinal fluid and blood of subhuman primate. Life Sci. 52: 745-749, 1993.
64. 2 receptor changes in major depression. Biol. Psychiatry 27: 489-496, 1990.
65. ZACZEK, R., BATTAGLIA, G., CULP, S., APPEL, N. M., CONTHERA, J. F. AND DE SOUZA, E. B.: Effects of repeated fenfluramine administration on indices of mono-amine function in rat brain: Pharmacokinetic, dose response, regional specificty and time course data. J. Pharmacol. Exp. Ther. 253: 104-112, 1990.